The overall goal is to achieve image guided and triggered release cytotoxic doses of gemcitabine to treat pancreatic tumors to alleviate resistance, systemic toxicity and off target issues. We aim to develop and characterize a theranostic nanoparticle based drug platform that can be triggered by acoustic changes induced by ultrasound for gemcitabine release in cells and in a pre-clinical pancreatic cancer model.The work to be performed at Northwestern University will be under the direction of Dr. Dong-Hyun Kim, PhD, Assistant Professor, Department of Radiology, Feinberg School of Medicine. Dr. Kim will oversee for synthesis and validation of the nanoparticles at Northwestern University.
|Effective start/end date||1/24/18 → 12/31/20|
- Medical College of Wisconsin (Agreement 6/20/18)
- Focused Ultrasound Foundation (Agreement 6/20/18)